12
Clinical insight
P R O B E
• V o l . L I I I • N o . 3 • A p r – J u n 2 0 1 4
de novo,
b
-glycyrrhetinic acid from
G glabra
is a potent inhibitor of the
classical complement pathway.
60-63
Balsamodendron mukul
,
Rubia
cordifolia
,
Emblica officinalis
,
G glabra
,
and
Moringa pterygosperma
have potent
antioxidant actions.
64-70
B mukul
has
strong anti-inflammatory potential.
71
G glabra
and
M pterygosperma
have
also been reported for its anti-
inflammatory properties.
72,73
T cordifolia
improves the phagocytic
and intracellular bactericidal capacities
of neutrophils.
74
Glycyrrhizin from
G glabra
has potent antiviral activity.
75
Emblica officinalis
has antibacterial
properties, especially against
Escherichia coli
,
Klebsiella pneumoniae
,
Klebsiella ozaenae
,
Proteus mirabilis
,
Pseudomonas aeruginosa
,
Salmonella
typhi
,
Salmonella paratyphi
A and
B, and
Serratia marcescens
.
76
Rubia
cordifolia
has antibacterial properties.
77
M pterygosperma
possesses antibacterial
and antiviral properties and inhibits
the growth of gram-positive and
gram-negative bacteria such as
E coli
,
S typhi
, and
S paratyphi
.
78
T cordifolia
and
E officinalis
have antipyretic
properties.
79,80
B mukul
is beneficial
in RTIs, including chronic tonsillitis,
pharyngitis, chronic bronchitis, nasal
catarrh, and laryngitis.
81
G glabra
is an
expectorant and hence is beneficial in
asthma, acute or chronic bronchitis,
and chronic cough.
82-84
Conclusion
The outcome of this meta-analysis,
which included 38 clinical studies,
carried out between 1958 and 2001,
in 2765 patients with RTI indicated
significant clinical efficacy and safety
of Septilin tablets. The cumulative
data analysis revealed significant
clinical improvement with adequate
symptomatic relief in Septilin-
treated patients. Adverse events were
negligible (< 1%) in Septilin-treated
patients and did not necessitate
withdrawal of the drug. The overall
drug compliance was very good.
Therefore, it may be concluded that
Septilin tablets are clinically effective
and safe in patients with RTIs.
Septilin, a multi-ingredient formula,
has immunomodulatory activity and
enhances natural immunity. It is
also a safe and effective adjuvant to
antimicrobials in the management
of recurrent infections. When
coprescribed with antibiotics, Septilin
ensures faster recovery, reduces the
duration and cost of therapy, besides
preventing reinfections.
References
1.
Cooper RJ et al.
Ann Intern Med
.
2001;134:509–517.
2.
Garibaldi
RA.
Am
J
Med
.
1985;78(6B):32–37.
3.
Fendrick AM, et al.
Arch Intern Med
.
2003;163(4):487–494.
4.
Kirkpatrick
GL.
Prim
Care
.
1996;23(4):657–675.
5.
Young MT.
Infect Dis Clin N Am
.
2004;18:919–937.
6.
Denny FW Jr.
Am J Respir Crit Care
Med
. 1995;152(Suppl pt 2):S4–S12.
7.
Musher DM.
NEJM
. 2003;348:1256–
1266.
8.
Monto AS, et al.
Clin Infect Dis
.
2003;36:253–258.
9.
Green S.
Singapore Medical J
.
2005;46(6):270–273.
10.
Agarwal NK, et al.
Med Surg
.
1986;26(5):25–27.
11.
Gaunekar L, et al.
The Antiseptic
.
1988;85(4):190–191.
12.
Gokhale SG, et al.
Curr Medical Pract
.
1958;2(10):616–619.
13.
Koti ST.
Probe
. 1992;XXXI(4):325–328.
14.
Mishra DN, et al.
Med Surg
.
1981;XXI(5):42.
15.
Miglani VP.
Capsule
. 1983;2:32.
16.
Nigam P, et al.
Med Surg
. 1985;2:28–
30.
17.
Sheth SC, et al.
J Indian Med Prof
.
1959;5:2767.
18.
Bhasin
RC.
Indian
Practit
.
1990;43(1):83–86.
19.
Sarkar
SK,
et
al.
Probe
.
1986;XXV(3):273–276.
20.
Luley S, et al.
Indian Practit
.
1984:1045–1049.
21.
Roy VD.
Probe.
1989;XXVIII(3):200.
22.
Khan
A,
et
al.
Probe
.
1984;XXIII(4):226–227.
23.
Mukherjee
D.
Probe
.
1984;XXIII(4):211–212.
24.
Tawde UJ.
Probe
. 1981;XX(3):196–198.
25.
Garga MK.
Probe
. 1980;XIX(3):201–
203.
26.
Cooper RAF, Merchant NR.
Indian J
Otolaryngol
. 1958;10(3):141–147.
27.
Grewal DS, et al.
Auris Nasusu Larynx
.
1985;12(2):95–101.
28.
Roy S.
Probe
. 1992;XXXI(2):146–156.
29.
Sharma SC, et al.
Indian J Pharmacol
.
1990;22(2):103–105.
30.
Singh BPM.
Indian Medical J
.
1992;86(1):12–13.
31.
Chugh JS.
Probe
. 1984;XXIV(1):28–31.
32.
Das
MR,
et
al.
Probe
.
1988;XXVII(4):254–260.
33.
De Sequeira PA.
Probe
. 1979;
XIX(1):43–44.
34.
Gadre KC, et al.
Probe
. 1964;III(3):
99–101.
35.
Vishwakarma
SK.
Probe
.
1979;XVIII(2):85–88.
36.
Rastogi
PK,
et
al.
Probe
.
1982;XXI(3):205–208.
37.
Bhatia BPR, et al.
Capsule
. 1978;4:79.
38.
Banerjee D.
Capsule
. 1988:99.
39.
Dass MR.
Curr Medical Pract
.
1988;32:1–6.
40.
Gadekar
HA,
et
al.
Probe
.
1986;XXV(2):164–165.
41.
Motwani
VB,
et
al.
Probe
.
1982;XXII(1):32–34.
42.
Lumba
SP,
et
al.
Probe
.
1983;XXII(3):178–780.
43.
Nair SS.
Capsule
. 1981;6:128.
44.
Sarkar M.
Capsule
. 1983;5:104.
45.
Tawde U, et al.
Med Surg
. 1987;2:5–8.
46.
Lakshmipathi G, et al.
J Indian Medical
Assoc
. 1962;4:174–175.
47.
Nehru
V.
Indian
Practit
.
2001;54(7):501–505.
48.
Naylor CD.
BMJ
. 1997;315:617–319.
49.
Bailar JC.
NEJM
. 1997;337:559–561.
50.
Huque MF.
Proc Biopharm Sect Am
Stat Assoc
. 1988;2:28–33.
51.
Lau J, et al.
NEJM
. 1992;327:248–254.
52.
Jenicek M.
J Clin Epidemiol
.
1989;42:35–44.
Kshirsagar M, et al.
Meta-analysis of Efficacy and Safety Studies of Septilin Tablets
